Immix Biopharma Reports Initial Data from US Trial of NXC-201 CAR-T Therapy for AL Amyloidosis

MT Newswires Live12-20

Immix Biopharma (IMMX) on Thursday reported initial clinical data from the first four patients in its ongoing trial of NXC-201 CAR-T cell therapy for relapsed/refractory AL Amyloidosis.

All four patients normalized their disease markers within 30 days of treatment, with two achieving a complete response, while the other two showed minimal residual disease negativity in the bone marrow.

The treatment demonstrated good tolerability, with no neurotoxicity, severe cytokine-release syndrome, febrile neutropenia, treatment-related infections, cardiac toxicity, or deaths, the biopharmaceutical company said.

Immix Biopharma said it intends to proceed with enrollment, expecting interim data in Q2 or Q3 2025 and final topline results by Q2 or Q3 2026.

Shares of Immix Biopharma were up 2.8% in recent Thursday trading.

Price: 2.21, Change: +0.11, Percent Change: +5.33

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2492105706?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-12-20 00:38","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2492105706","market":"hk","top_or_hot":-1,"title":"Immix Biopharma Reports Initial Data from US Trial of NXC-201 CAR-T Therapy for AL Amyloidosis","media":"MT Newswires Live","content":"<html><body><p> Immix Biopharma (IMMX) on Thursday reported initial clinical data from the first four patients in its ongoing trial of NXC-201 CAR-T cell therapy for relapsed/refractory AL Amyloidosis.</p><p>All four patients normalized their disease markers within 30 days of treatment, with two achieving a complete response, while the other two showed minimal residual disease negativity in the bone marrow.</p><p>The treatment demonstrated good tolerability, with no neurotoxicity, severe cytokine-release syndrome, febrile neutropenia, treatment-related infections, cardiac toxicity, or deaths, the biopharmaceutical company said.</p><p>Immix Biopharma said it intends to proceed with enrollment, expecting interim data in Q2 or Q3 2025 and final topline results by Q2 or Q3 2026.</p><p>Shares of Immix Biopharma were up 2.8% in recent Thursday trading.</p><p>Price: 2.21, Change: +0.11, Percent Change: +5.33</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Immix Biopharma Reports Initial Data from US Trial of NXC-201 CAR-T Therapy for AL Amyloidosis</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nImmix Biopharma Reports Initial Data from US Trial of NXC-201 CAR-T Therapy for AL Amyloidosis\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-12-20 00:38 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.mtnewswires.com/><strong>MT Newswires Live</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Immix Biopharma (IMMX) on Thursday reported initial clinical data from the first four patients in its ongoing trial of NXC-201 CAR-T cell therapy for relapsed/refractory AL Amyloidosis.All four ...</p>\n\n<a href=\"https://www.mtnewswires.com/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IMMX","symbol_name":"Immix Biopharma, Inc","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2492105706","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2492105706","pubTimestamp":1734626328,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Immix Biopharma (IMMX) on Thursday reported initial clinical data from the first four patients in its ongoing trial of NXC-201 CAR-T cell therapy for relapsed/refractory AL Amyloidosis.All four patien","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IMMX":"Immix Biopharma, Inc","BK4022":"陆运","BK4104":"贸易公司与经销商","IE00B19Z6F94.USD":"Legg Mason Royce - US Smaller Companies A Acc USD","BK4230":"旅客陆运","IE0034390439.USD":"FTGF ROYCE US SMALLER COMPANIES \"A\" (USD) D","BK4139":"生物科技","NXC":"Nuveen California Select Tax-Fre","AL":"航空租赁公司","BK4572":"航空租赁","CAR":"安飞士"},"translate_title":"Immix Biopharma报告NXC-201 CAR-T疗法治疗AL淀粉样变性美国试验的初步数据","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AL":1,"CAR":1,"NXC":1,"IMMX":0.9},"content_text":"Immix Biopharma (IMMX) on Thursday reported initial clinical data from the first four patients in its ongoing trial of NXC-201 CAR-T cell therapy for relapsed/refractory AL Amyloidosis.All four patients normalized their disease markers within 30 days of treatment, with two achieving a complete response, while the other two showed minimal residual disease negativity in the bone marrow.The treatment demonstrated good tolerability, with no neurotoxicity, severe cytokine-release syndrome, febrile neutropenia, treatment-related infections, cardiac toxicity, or deaths, the biopharmaceutical company said.Immix Biopharma said it intends to proceed with enrollment, expecting interim data in Q2 or Q3 2025 and final topline results by Q2 or Q3 2026.Shares of Immix Biopharma were up 2.8% in recent Thursday trading.Price: 2.21, Change: +0.11, Percent Change: +5.33","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2492105706"}